Overall, this study suggests that about 70% of MPM patients are potentially sensitive to MV oncolytic activity and that this activity depends on defects in the intracellular innate antiviral response in MPM tumor cells rather than on CD46 overexpression on the cell surface. The gene discussed is CD46; the disease is neoplasm.